Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

L. S. Tzouvelekis, A. Markogiannakis, E. Piperaki, M. Souli, G. L

Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-α in patients with visceral leishmaniasis I.M. Medeiros,

L. Boyanova Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

Clinical Microbiology and Infection

Herpes zoster in non-hospitalized children

An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia A.R. Akram, J.D. Chalmers, J.K. Taylor, J. Rutherford,

Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis G. Choudhury,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Bernard Grenier Clinical Microbiology and Infection

R. Cantón Clinical Microbiology and Infection

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

Single-dose extended-release oral azithromycin vs

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

V.E. Nambudiri, R.C. Dwyer, C.A. Camargo, T.S. Kupper, D.J. Pallin

Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. H. Wisplinghoff, H. Seifert,

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Clinical Microbiology and Infection

Cutaneous sporotrichosis: the old iodide treatment remains effective

Vector control: a cornerstone in the malaria elimination campaign

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Training for the infectious diseases speciality in Norway

G. Höffken Clinical Microbiology and Infection

Community-acquired pneumonia: the evolving challenge

Retrospective study of CMV retinitis in patients with AIDS

Laboratory diagnosis and biosafety issues of biological warfare agents

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Elements of design: the knowledge on which we build

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

Levofloxacin in the treatment of ventilator-associated pneumonia

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin King A. , Bathgate.

Laboratory diagnosis of Clostridium difficile disease

Recent developments in staphylococcal scalded skin syndrome

A. Bryskier Clinical Microbiology and Infection

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Effect of step-down therapy of ceftriaxone plus loracarbef versus parenteral therapy of ceftriaxone on the intestinal microflora in patients with community-acquired.

Community-acquired pneumonia: epidemiologic and clinical consideration

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

Fibronectin concentrations in catheter sepsis

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Clinical infection services—the Leiden experience

Statin use and clinical outcomes among pneumonia patients

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis C. Piketty, C. Bardin, J.

Predictors of clinical and microbiological treatment failure in patients with methicillin- resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective.

Sanford Chodosh Clinical Microbiology and Infection

Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia U. Hohenthal, S. Hurme, H. Helenius,

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Carratalà J. Clinical Microbiology and Infection

New patterns of HIV-1 resistance during HAART

J.A. Pérez-Molina, F. Fernández Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Localized Mycobacterium avium complex infection in a patient on HAART

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Presentation transcript:

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola, I. Velancsics, B. Leroy, M. Rangaraju, P. Decosta Clinical Microbiology and Infection Volume 9, Issue 7, Pages 691-703 (July 2003) DOI: 10.1046/j.1469-0691.2003.00678.x Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Clinical cure rates among patients with a confirmed diagnosis of community-acquired pneumonia (CAP) who received at least one dose of telithromycin 800 mg (modified intent to treat; mITT) and met the per-protocol criteria (PPc) at the test of cure assessment and late post-therapy visit. Clinical Microbiology and Infection 2003 9, 691-703DOI: (10.1046/j.1469-0691.2003.00678.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Individual plasma concentrations and mean plasma concentrations of telithromycin (log plot) vs. time in adult patients with a confirmed diagnosis of CAP who received telithromycin 800 mg once daily. Clinical Microbiology and Infection 2003 9, 691-703DOI: (10.1046/j.1469-0691.2003.00678.x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions